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The interest in non-surgical approaches to contraception and fertility control in female dogs has
increased in recent years. In this study the effect of an aromatase inhibitor (finrozole) was evaluated in
fur production animals, farmed blue fox vixens, as a model for contraception in bitches. A total of 80
vixens were divided into 4 groups, receiving orally placebo (A) or finrozole 0.5 mg/kg (B), 3.5 mg/kg (C)
or 24.5 mg/kg (D) for 21 consecutive days beginning in the pre-ovulatory period of heat. Monitoring of
the vixens included clinical signs of heat, measurement of vaginal electrical resistance (VER) as well as
oestradiol and progesterone concentrations in plasma. The approximate relation of the start of treatment
to ovulation varied from 11 days before to one day after ovulation provided that the LH peak occurred 0.5
e2 days before the VER peak and ovulation was then estimated to occur 2 days after the LH peak. Seventy
vixens were artificially inseminated within 8 h after a 50 U decline in vaginal electrical resistance was
detected. Ten vixens were not inseminated. Pregnancy was confirmed by transabdominal ultrasound
examination and birth of cubs was recorded. The pregnancy rates in the groups were 89.5% (A), 81.3% (B),
55.6% (C) and 52.9% (D). The average number of live born pups in the four groups was 9.4 (A), 7.0 (B), 5.8
(C), and 3.8 (D), respectively. No deleterious effects (for instance malformations) of finrozole on pups
could be verified. The administration of finrozole did not have a significant effect on oestradiol pa-
rameters and VER values in vixens. Progesterone values were significantly higher in treatment groups
compared with the placebo group. The results indicate that pregnancy could be avoided by finrozole
provided that doses of 3.5 mg/kg were used and the treatment was initiated at least four days before
the day of artificial insemination. This corresponds with two to six days before ovulation provided that
the LH peak occurred 0.5e2 days before the VER peak and that ovulation then occurred in average 2 days
after the LH peak.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ed as abstracts and posters in
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Due to a steady increase in dog populations worldwide, there is
an increased awareness amongst dog breeders and dog owners to-
wards controlling reproduction. The most common way of control-
ling reproduction in dogs is surgical removal of the gonads. This,
however, is not an option for dog breeders who wish to use their
dogs for future breeding. In bitches, possibilities for contraception,
defined as suppression of oestrus, are based on hormonal treat-
ments. Hormonal contraception in bitches has included the use ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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analogs that act either directly by blocking reproductive hormone
receptor-mediated events or indirectly block conception via negative
feedback mechanisms [1]. However, many of these treatments are
associated with a high incidence of side effects, which can be
detrimental for individuals intended for breeding in the future.
Other possibilities of contraception in bitches are via activation of
the immunological system with vaccinations against GnRH, the
luteinizing hormone (LH) receptor and the zona pellucida proteins
[2].
Compounds for prevention or modification of oestrogens are
classified as anti-oestrogens. Some of these are GnRH analogs and
aromatase inhibitors that block oestrogen synthesis [3]. Another
anti-oestrogenic group of drugs are oestrogen receptor blockers [4].
Knowledge of the effect of receptor blocker anti-oestrogens in dogs
is still scarce. Most studies have been carried out using tamoxifen,
which seems to act more like an agonist than antagonist, inducing
signs of heat in bitches [3].
Another possibility for contraception in female dogs might be
the use of finrozole, a non-steroidal aromatase inhibitor. The effect
of finrozole has been evaluated for treatment of urinary disease in
men [5]. Due to a high demand of reversible contraception in vet-
erinary medicine for female dogs, several yet unpublished studies
were initiated by the sponsor in order to investigate the function
and mechanism of finrozole. The idea was to develop a compound
for prevention of heat and for contraception in female dogs,
without side-effects related to the use of, for instance, gestagens.
Aromatase is a cytochrome p450 enzyme which catalyses the
conversion of androgens to oestrogens [5]. Aromatase activity is
increased when oestradiol-17b concentration is elevated in
response to FSH inducing follicular growth. Aromatization is the
rate limiting step in oestrogen formation and a target for devel-
opment of agents to block the synthesis of oestradiol [6]. Blockade
of this step allows treatment of diseases dependent of oestrogens,
such as for instance hormone dependent breast cancer in human
medicine [7]. Use of aromatase inhibitors has also been studied in
treatment of endometriosis related pain in humans [8]. In veteri-
nary medicine, aromatase inhibitors have been used for treating
diseases of the prostate gland in male dogs, since oestrogen plays
an important role in the development of benign prostatic hyper-
plasia (BPH) [9].
In a study by Yapura et al. [10] the potential of non-steroidal
aromatase inhibitors as an alternative for controlling ovarian
function in cattle has been investigated. Letrozole treatment was
found to extend the lifespan of the dominant follicle resulting in a
delay in the emergence of the next follicular wave or in delayed
ovulation [11]. Letrozole treatment in cattle had a consistent
luteotrophic effect and treatment was associated with develop-
ment of a larger CL and/or higher circulating concentrations of
progesterone [12].
Maintaining dog populations for research purposes raises
several ethical issues, as one of the strongest objections is the use of
a pet animal for research. To avoid this, a closely related canine
species was selected as a model, under clinical field trial conditions,
without sacrifice of the animals. Farmed blue fox vixens (Vulpes
lagopus) are fur production animals, and housed in individual pens
on farm conditions since their weaning (age about 8 wks). As they
present hormonal patterns similar to those of female dogs [13] they
are suitable as model species for domestic dogs.
Farmed blue foxes, colour mutations of the arctic fox, are
monoestrous seasonal breeders, with reproductive activity during
the spring months of February to May. The oestrous cycle of a blue
fox vixen is divided into four stages; pro-oestrus, oestrus,
metoestrus and anoestrus. As described by Farstad [14], no physical
signs of approaching heat can be detected, on average, until twoweeks before the LH-peak, indicating the start of pro-oestrus, the
period of follicle growth in ovaries. Before this, approximately one
month prior to the LH peak, the first follicles appear on the ovarian
surfaces [15]. Clinical signs of early follicular development are
swelling of the vulva, increased frequency of urination and vocali-
zation. The duration of pro-oestrus is usually one week. However, it
may extend to 12e24 days andmay be shorter inmid-to late season
than early in the season [14].
The majority of the vixens come into oestrus, ie. arewilling to be
mated, in mid-March to mid-April [14]. The duration of oestrus
ranges between one to 8 days, the average being 4e5 days [16]. The
maximum swelling of the vulva is usually observed on the day of
onset of oestrus [14]. The onset of oestrus in vixens may vary
considerably in regard to the LH peak and ovulation and may start
simultaneously with the LH peak, a day after the LH peak or even at
ovulation two days after the LH peak [17,18]. Oestrus is character-
ized by ovaries containing late preovulatory follicles or ovulated
follicles and by ovarian steroid production shifted from predomi-
nantly oestrogens to progesterone [14]. Ovulation, occurring within
the period of oestrus, is followed by a period of extended luteal
function. Metoestrus is defined as the luteal phase in the blue fox. In
pregnant and non-pregnant vixens, the whole period from ovula-
tion to regression of corpora lutea is termed metoestrus. After
metoeostrus, anoestrus begins, lasting on average for up to 9
months and indicating the period of ovarian rest [14].
Peak plasma oestradiol values in vixens coincide with the LH
peak, i.e. 1e2 days before the onset of oestrus. Electrical resistance
of the vagina varies during oestrus [19]. In most vixens, the elec-
trical resistance reaches the peak 0.5e2 days after the LH peak
[17,18], close to the first day of sexual receptivity. The decline phase
of the resistance occurs 2e6 days after the LH peak. Ovulations
occur spontaneously 1e3 days after the LH peak (on average:
LH þ 2 days) and oocytes are ovulated in the developmental stage
of primary oocytes [17,20]. The length of gestation in blue foxes is
approximately 52 days from mating to parturition but may vary
between 48 and 57 days, depending on whether the initiation of
the gestation is calculated from the time of the LH peak, ovulation
or fertilization [14].
The aim of the present study was to evaluate the contraceptive
effect of oral administration of finrozole in vixens as a model of
contraception in bitches. Determination of an efficacious dose of
finrozole for prevention of pregnancy was performed by assessing
the concentrations of oestradiol and progesterone and the inci-
dence of pregnancies.
2. Materials and methods
2.1. Animals
The study was a placebo controlled open study, with 80 vixens
(Vulpes lagopus) selected out of 190 individuals during the breeding
season of 2009. Selection of 1.5e4.5 year old vixens, that had one to
four previous whelpings, was done based on body condition (with
score 3 by Kempe et al. [21]), and weight ranging from 6.7 to
10.9 kg. Large sized (>11 kg) vixens were excluded as they are more
likely known to be barren or to lose their pups during pregnancy or
right after birth [22]. Because all animals had been raised together
since birth, the acclimatization period could be reduced and began
14 days before the anticipated beginning of the heat. For inclusion
into the study, the vixens were first examined in the end of
February and twice in March by the responsible study veterinarian
in order to exclude animals with pathological conditions that could
interfere with the outcome of the study. Every vixen was individ-
ually weighed and marked with a microchip (AVID Friendship™ by
Avid Identification Systems, Inc. California, USA), enabling
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Identification Systems, Inc. California, USA). The vixens were
dewormed with ivermectin (Ivomec Comp, Merial SAS, France,
1.5 kg Ivomec/1000 kg feed) twice at 4 day interval before the
beginning of the study. All procedures were conducted under
approval from the Animal Experimental Board in Finland (ELLA,
decision STH904A, licence 8.12.2008ESLH-2008-09367/Ym-23).
2.1.1. Housing and general management
All vixens were housed individually in an outdoor shed at MTT
Agrifood Research Finland facility in Kannus, Finland, in cages
(Length 110 cm x Width 105 cm x Height 70 cm). Each cage
included a wire-mesh shelf (Length 105 cm x Width 25 cm),
enabling the vixens to climb and exhibit species like behaviour. For
this purpose, the vixens were also provided with an activity object,
such as a piece of wood, to play with during the entire duration of
the study. For whelping, the vixens were provided with a wooden
whelping nest box in their cages.
The vixens were fed on a restricted breeder’s diet in order to
optimise breeding results [23]. The vixens were fed once daily,
January to March at 2 pme4 pm and April to June at 10 am to 5 p.m.
The amount of feed distributed daily ranged between 150 and
600 g. Fresh water was provided by the municipal water supply via
a non-freezing automatic water supplier.
2.1.2. Outdoor temperature and hygrometry
The variation in outdoor temperature was between 24 C
and þ28 C and the hygrometry 20e100% depending on the
weather and the time of year. A day/night cycle of 11 h of light and
13 h of dark per day was maintained in March and early April.
During summer the hours of daylight increased from 12.5 h in
March to 20 h and 20 min in June.
2.2. Allocation of groups
A total of 80 vixens were randomly allocated into four treatment
groups (20 vixens per group) according to the oral administration
of either placebo or finrozole in different doses: group A (placebo),
group B (0.5 mg/kg), group C (3.5 mg/kg) and group D (24.5 mg/kg).
The progression of heat was monitored by measurement of
vaginal electrical resistance (VER) in order to define the start of
treatment. The original purpose was to begin administration of the
aromatase inhibitor when an ascent in VER values was detected
indicating ovarian follicular activity [14,18]. Due to an earlier onset
in the breeding season of many individuals from the original
research population of 190 vixens, this selection criterion was
changed to include the vixen into the study so that she had received
at least one dose of treatment before she was artificially insemi-
nated. This meant the vixen had eaten at least one dose of treat-
ment in themorning if shewas inseminated in the afternoon. In our
data, we had two vixens whose artificial insemination (AI) and
initiation of treatment occurred on the same day (Fig. 1).
From each treatment group of 20 vixens animals were randomly
picked into four subgroups of 20 vixens (five from each group A, B,
C and D) according to the time points of administration initiation of
finrozole. In the first, second, third and fourth subgroup, adminis-
tration of finrozole was initiated on March 26th 2009, March 27th
2009, April 2nd 2009 and April 3rd 2009, respectively.
The preliminary study, during which this data was collected,
was designed as a pharmacological dose determination study. For
this specific publication, however, in order to evaluate parameters
of reproductive physiology, the data was re-organised and analysed
taking into consideration the stage of heat in relation to the initi-
ation of treatment. By this, the four groups A, B, C and D were
further re-organised into Placebo (A, placebo pregnant), andtreatment groups (BCD, pregnant and BCD, not pregnant). The
placebo, not pregnant group, consisted of only two vixens, whose
VER measurements and hormone concentrations are not shown in
the graphs. The pregnancy rates in each treatment group were
assorted on the basis of the number of days between initiation of
treatment and first AI as the length of this period affected the
pregnancy results.
2.3. Monitoring of heat related ovarian activity
The onset of ovarian follicular activity was detected by clinical
observation of swelling of external genitalia. Controls of vixens
regarding the initiation of vulval swelling was performed twice
weekly beginning in March. After detecting the first sign of vulval
swelling, the further process was documented daily by rating the
swelling degree with a 0 to 3 scale, where 1 stands for the first
clinical signs of increasing oestrogen secretion, 2 stand for medium
swelling and 3 for maximum swelling indicating maximum oes-
trogen secretion with a VER value  200 U. Measurement of the
electrical conductivity was performed using amodified Ohm-meter
(SiLi Heat-detector, Lima A/S, Sandnes, Norway). It was started
when scale 3 vulval swelling had been reached in order to monitor
the rise in VER indicating the changes in vaginal secretion due to
decreasing oestrogen concentrations. Measurements were
continued daily until the day of first AI, indicated by a decrease of at
least 50 U in VER values.
2.4. Administration of finrozole
The aromatase inhibitor was administered orally once a day for
21 consecutive days. Finrozole was available in capsules packed in
labelled plastic jars, stored at 15e25 C. Each vixen received one
capsule once a day. The capsules were opened and the content was
mixed in a small amount of feed. The feed containing the medica-
tionwas fed to the vixens prior to their daily ration. All vixens were
monitored during feeding to ensure sufficient oral administration.
Incomplete consumption of the feed was observed in 7 vixens (2 in
group B, 1 in group C, and 4 in group D). One vixen per group B and
C and two vixens in group D refused feeding once. Two vixens in
each of groups B and D refused feeding on three different occasions.
One vixen in group D refused consumption of the feed during 5
days. The timeline of incomplete administration of the compound
ranged sporadically from day 8 to day 21 of administration. Because
only one vixen whose treatment was initiated 1 day before first AI
gave birth (of the 7 vixens associatedwith incomplete consumption
of the feed) and because the refusals occurred during the last two
weeks of administration of finrozole, those individuals were
considered not to have affected the results. Necessary precautions
were taken during drug administration by wearing single-use
disposable clothing during handling of capsules, mixing the con-
tent into the feed and administration of the feed.
2.5. Semen collection and AI
Males of proven fertility were used as semen donors. Semenwas
collected every other day throughout the breeding season. The
males and the vixens were transported from their cages to the
semen collection and insemination facility using individual cages
for each animal. Maximum of three males were collected at a time
and the freshly collected non pooled semenwas used to inseminate
the vixens. If more semenwas required for the day’s inseminations,
then three new males were picked up for semen collection.
An unsedated male at a time was placed in a semen collection
stand and the second fraction of the ejaculate (0.2e1 ml of undi-
luted semen) was collected by digital manipulation into a glass vial
Fig. 1. Distribution of vixens (n ¼ 70) regarding the initiation of treatment before first AI.
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According to the colour and consistency of the collected semen, the
fraction was diluted with EDTA (stored at room temperature
in þ20 C) up to a total volume of 2e3 ml. Watery fractions were
discarded, thick milky fractions were diluted with up to 3 ml of
EDTA and less milky fractions with up to 2 ml of EDTA. A small
sample of diluted semen was analysed under a light microscope (x
400) to check themotility of the spermatozoa. Sperm concentration
was not counted. For AI, diluted semen with at least 70% progres-
sivelymotile spermwas required. Prior to AI, the diluted semenwas
stored at þ 20 C from 30 min to 3 h between inseminations.
Transcervical insemination was performed using a Norwegian
catheter [24,25]. Sterile catheters and sheaths covering the metal
catheters during vaginal introductionwere stored atþ30 C prior to
AI. An unsedated vixen was fixed by the neck and tail in an
insemination rack. The vulva was disinfected with 70% EtOH before
inserting a sheath into the vagina, through which the Norwegian
catheter was guided to the opening of the cervix. After passing the
cervix, 1 ml of fresh diluted semen was deposited into the uterus
with a syringe.
According to the normal routine on fox farms, the vixens are
predominantly inseminated once or twice. Based on the present
data and current literature [25], it seems that one insemination is
enough if the vixen has a clear rise and fall VER curve. If VER re-
mains high for a longer time, a second insemination ensures that
timing will be better with respect to oocyte maturation. The second
insemination occurs two days after the first insemination according
to the VER values. This routine was chosen in the present study
although it meant different numbers of AIs per vixen. Finally, 52
vixens were inseminated once,17 vixenswere inseminated twice (4
in group A, 5 in group B, 3 in group C and 5 in group D), and one
vixen (group A) was inseminated four times due to a two-phase
resistance curve. Ten vixens were not inseminated. In eight of
them (4 in group B, 1 in group C and 3 in group D), the intravaginal
insertion of the probe of the heat detector was impossible due to
vulval swelling progressing only to scales 1 and 2. The remaining
two vixens were not VER measured and were not inseminated due
to a human error (group A) and due to an injured vagina (group C).2.6. Blood sampling
In each vixen two weekly blood collections were performed
throughout the first three weeks of administration. Thereafter
sampling was reduced to a once a week schedule, resulting in a
total of 11 blood samples per vixen. All vixens were anaesthetized
during collection of blood samples. For blood sample collection the
vixens were transported to the blood collection facility in a trans-
port cage system containing individual cages for each vixen. The
vixens were anaesthetized with a combination of medetomidine
(Dorbene 1 mg/ml, Laboratorios SYVA S.A., Spain) and tiletamine-
zolazepam (Zoletil 100, 250 mg/ml þ 250 mg/ml, Virbac, France).
Five ml of medetomidine were mixed with tiletamine-zolazepam
powder. Each vixen was treated with 0.2 ml of this combination
intramuscularily containing 0.2 mg of medetomidine and 20 mg of
tiletamine-zolazepam. Anaesthesia lasted for 30 min. Blood was
collected from vena saphena after clipping a small area of fur and
wiping the skin with 70% EtOH.
Four ml of blood was collected into two lithium heparin tubes
(Terumo Europe N$V., Leuven, Belgium) which were centrifuged
3000 rpm for 10 min and plasma transferred into two separate
tubes, each containing at least 0.5 mL of plasma. For shipment to
the diagnostic laboratory at the National Veterinary School in Lyon,
France for hormone analyses, the samples were placed on dry ice.
2.6.1. Oestradiol
For oestradiol, the samples were assayed by using a Packard RIA
STAR solid scintillation counter. Oestradiol assays were performed
using the kit ESTRADIOL-2 (Clinical Assays) supplied by Diasorin,
92160 - Antony (France), validated for dogs, without any changes to
the usual kit protocol. The analytical sensitivity, calculated as the
apparent concentration of analyte which was distinguishable from
the zero calibrator (two standard deviations below zero) was
5.0 pmol/L, the intra-assay coefficient of variation ranged between
2.6% and 6.1%, the inter-assay coefficient of variation ranged be-
tween 4.6% and 6.1%. Samples for which the apparent concentration
was below the analytical sensitivity of the assay were assigned to a
concentration equal to zero. All the analyses were performed with
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same control serum (CE, target values: from 336 to 504 pmol/L).2.6.2. Progesterone
Progesterone was measured by a solid-phase, competitive
chemiluminescent enzyme immunoassay, using the reagents
Immulite 2000 Cortisol L2KPW2 provided by Siemens Healthcare
Diagnostics SAS and validated for dogs. The analytical sensitivity
(quantification limit) for the assay was 0.7 nmol/L and the working
range is from 0.7 to 127 pg/mL. The within-run and total precisions
range between 9.5% (21.3 nmol/L) and 21.7% (0.46 nmol/L). Samples
for which the apparent concentration was below the quantification
limit of the assay were assigned a concentration equal to zero. All
the analyses were performed with the same batch of reagents (ref
304) and controlled with the specific steroid controls of Siemens
(CON 6, batch 022, three levels).2.7. Confirmation of pregnancy
During the 8th, 9th or 10th blood sampling occasion corre-
sponding to the period D23 to D46 after first AI, the anaesthetized
vixens (54 out of the 70 inseminated vixens. In the remaining 16
vixens, whelping was the verification of pregnancy) were sono-
graphically examined for pregnancy by an experienced veteri-
narian. Each vixen was placed on an examination table in dorsal
recumbency and the abdominal fur was sprayed with alcohol. Then
a 7.5 MHz linear probe of an Aloka SSD-DX Scanner (Tokyo, Japan)
was inserted on the abdominal skin and the uterus was scanned for
detection of foetuses. If live foetuses or clear signs of foetal
resorption were detected, conception was considered to have
occurred. All vixens were monitored for the delivery of pups
starting the day after the expected day of parturition (D52 after first
AI). The number of pups was recorded at birth and again one week
later. At birth, pups were inspected by lifting the roof of thewooden
whelping nest box. Dead pups were removed and examined for
malformations. At one week of age, during gender determination,
each pup was lifted from the nest for examination of malforma-
tions. Pregnancy rates were calculated based on both ultrasonog-
raphy confirming pregnancy and pups born.Table 1
Inseminated (n), pregnant (n, %) andwhelping (n/%) vixens in group A (placebo), and
finrozole treated groups B (0.5 mg/kg), C (3.5 mg/kg), and D (24.5 mg/kg).
Group Inseminated Pregnant Whelping
n n % N %
A 19 17 89.5 16 84.2
B 16 13 81.3 8 50.0
C 18 10 55.6 9 50.0
D 17 9 52.9 6 35.3
Total 70 49 70.0 39 55.72.8. Statistical analysis
All data were first subjected to testing for normal distribution.
Transformation (log 10) of data was used where appropriate. Oes-
tradiol and progesterone profiles and electrical resistance in vaginal
mucus were analysed using analysis of variance with repeated
measurements (split-plot ANOVA, [26]; software: IBM SPSS Sta-
tistics version 24, release 24.0.0.0). In the General Linear Model for
repeatedmeasures, treatments (n¼ 4) were considered as between
subject factors (fixed effect) and periods (n ¼ 5) as within subject,
repeated factors (days, every two days together forming a period).
As a post testing procedure for oestradiol and progesterone con-
centrations at given points in time, the Tukey procedure was used
for pairwise comparisons and the Dunnett procedure for timewise
comparisons. Statistical testing for pup losses between placebo and
treatment groups was done using ChiSquare.
The effect of treatments (n ¼ 4) on pregnancy outcome was
analysed through ChiSquare testing. The effect of the treatments on
litter size was tested through analysis of variancewhere treatments
were used as independent factor and number of pups as outcome
variable. Thereafter, multiple comparisons were carried out by
Student’s t-test where appropriate.3. Results
The numbers of inseminated, pregnant and whelping vixens
recorded in each group are presented in Table 1. The 10 vixens
confirmed to be pregnant at ultrasound examination but with no
verified parturition have been included in the group of pregnant
vixens regarding VER and hormone concentrations shown in
Figs. 2e4.
On the day of initiation of the treatment, in themajority (n¼ 48)
of the 70 inseminated vixens, VER measurement had been per-
formed for at least 2 days. In eight vixens, VER had been deter-
mined just once, while 14 vixens were still at the stage of vulval
swelling (11 on scale 3, three on scale 2) and thus VER measure-
ment had not started. The mean period of VER measurements be-
tween initiation of treatment and the first AI was 3.7 ± 1.2 days. In
the placebo group (A, n¼ 19), this period was 4.3 ± 1.1 days, almost
one day longer than in vixens of groups B,C and D (n¼ 51) (3.5 ± 1.2
days).
As shown in Fig. 2, administration of the aromatase inhibitor
finrozole did not affect the pattern of VER before AI in either
treatment group when compared with group A (P > 0.20).
During the 21 day treatment period no significant differences
were found in the plasma oestradiol concentrations between the
placebo group and the treatment groups (p ¼ 0.70) (Fig. 3). The
levels of plasma oestradiol concentrations appeared normal in all
groups, following a typical pattern of vixens during heat. In the
pregnant and not pregnant treatment groups (BCD) and in the
placebo group (A), mean SD values before first AI and after first AI
were 21.3 (BCD pregnant), 33.4 (BCD not pregnant), 22.7 (placebo)
and 8.8 (BCD pregnant), 21.2 (BCD not pregnant), 11.7 (placebo),
respectively.
Mean progesterone patterns in the treatment groups resemble
that for placebo treated control vixens (group A). However, mean
progesterone values were significantly higher (P ¼ 0.023) both in
the pregnant and not pregnant treatment groups (BCD) compared
with the placebo group (Fig. 4).
The time difference between the peaks of oestradiol is shown in
Fig. 5. In this graph, values originating from blood samples and VER
measurements collected before the start of treatment are included.
The oestradiol concentration peaked five days before first AI in the
pregnant vixens of both the placebo group A and the pregnant
group BCD. In the not pregnant vixens of the treatment groups BCD,
the values were still rising on day 4 and no peak was yet evident.
In the BCD pregnant group, the time difference between the oes-
tradiol and VER peaks was four days. Mean VER values of days2 to
0 of the pregnant vixens of the placebo and not pregnant vixens of
the BCD group are not shown in Fig. 5 because from day 2 before
first AI to day 0, respectively, these vixens were under the influence
of treatment.
In Fig. 6, a bar chart shows the stage of heat at the initiation of
treatment, the number of days from initiation of treatment to AI
and the outcome (pregnant or not pregnant) in 70 inseminated
vixens. In this graph, all vixens showing sonographic signs of
Fig. 2. Vaginal electrical resistance (U) before first AI in vixens that became pregnant (A, placebo n ¼ 17 and BCD n ¼ 32) and in treated vixens that did not become pregnant (group
BCD n ¼ 19). Values are depicted as means ± SD. Horizontal bars indicate the treatment periods of individual vixens.
L. Lindh et al. / Theriogenology 152 (2020) 53e6358pregnancy were considered to be pregnant irrespective of whether
or not pups were delivered.
Pregnancy rates were about equal in group A (placebo 89.5%)
and group B (81.3%), but markedly reduced in treatment groups C
(55.6%) and D (52.9%) (Tables 1 and 2). For vixens that were
inseminated only once, the pregnancy rates in different groups
were 85.7% (A), 72.7% (B), 46.7% (C) and 41.7% (D). The results of
this study clearly indicate that administration of finrozole signif-
icantly prevented pregnancy if the treatment with finrozole at a
dosage of 3.5 mg/kg or 24.5 mg/kg was initiated at least 4 daysFig. 3. Mean oestradiol concentrations (pmol/L) throughout the experimental period in vixe
did not become pregnant (group BCD n ¼ 19). Horizontal bars represent the 21 days treatmbefore first AI, corresponding with 2e5.5 days before estimated
ovulation [14].
Whelping rates (percentages of inseminated vixens that
whelped) in different groups were 84.2% (16/19; n whelping/n
inseminated; A), 50.0% (8/16; B), 50.0% (9/18; C) and 35.3% (6/17;
D). In the entire BCD group, 45.1% of the vixens whelped (23
whelping/51 inseminated). Numbers of pups live at birth in
different groups were 151 (A), 55 (B), 52 (C) and 23 (D). The mean
numbers of pups live at birth per inseminated and whelping
vixens are presented in Table 3. Litter size ranged in differentns that became pregnant (A, placebo n ¼ 17 and BCD n ¼ 32) and in treated vixens that
ent period and indicate the treatment periods of individual vixens.
Fig. 4. Mean progesterone concentrations (nmol/L) throughout the experimental period in vixens that became pregnant (A, placebo n ¼ 17 and BCD n ¼ 32) and in treated vixens
that did not become pregnant (group BCD n ¼ 19). Horizontal bars represent the 21 days treatment period and indicate the treatment periods of individual vixens.
L. Lindh et al. / Theriogenology 152 (2020) 53e63 59groups from 4 to 13 (A), 4 to 12 (B), 2 to 10 (C) and 1 to 9 (D) pups
live at birth.
The percentages of whelping vixens experiencing pup loss be-
tween birth and one week thereafter was 68.8% in group A, 37.5% in
group B, 55.6% in group C, and 33.3% in group D. There was no
difference in pup loss between placebo and treatment groups
(P¼ 0.111). In litters of 19 vixens (11 A, 3 B, 4C and 1 D group vixens)
pups were lost in the first week of life. In one vixen of both group CFig. 5. Mean oestradiol concentrations (pmol/L) in relation to vaginal electrical resistance (U
in treated vixens that did not become pregnant (group BCD n ¼ 19). Oestradiol concentrat
treatment corresponding to the first two blood collections and VER measurements of vixen
periods of individual vixens.and group D the entire litter was affected. The percentages of pups
lost were 23.8% in group A, 5.5% in group B, 11.5% in group C, and
8.7% in group D.4. Discussion
We report a promising protocol for using aromatase inhibition
to prevent pregnancy in the farmed blue fox. The success is based) before first AI in vixens that became pregnant (A, placebo n ¼ 17 and BCD n ¼ 32) and
ions and VER values originate from measurements performed before the initiation of
s registered before the initiation of treatment. Horizontal bars indicate the treatment
Fig. 6. Illustration of the number of treatment days before first AI in individual vixens of group A (placebo n ¼ 19) and group BCD (finrozole n ¼ 51) together with the outcome of
insemination (pregnant: group A n ¼ 17, group BCD n ¼ 32 vs. not pregnant: group A n ¼ 2, group BCD n ¼ 19). Symbols in boxes indicate the stage of heat at the initiation of
treatment. S ¼ swelling of the vulva (all three scales), FU ¼ first day of ohm measurement, U ¼ 2 days of ohm measurements. (B), (C), (D) indicate group affiliation of vixens.
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that prevented pregnancy in the experimental vixens if treatment
was initiated at least four days before first AI (Tables 1 and 2). To the
authors’ knowledge, this is the first time a farmed fox was used as a
model for a domestic dog in a drug dose determination study to
prevent pregnancy. As Table 2 shows, there was considerable
variation in the treatment response in terms of the pregnancy
outcome, depending on the timing of onset of the treatment. If the
treatment was initiated early enough and if the dose was high
enough, the vixen did not become pregnant. The time limit for this
was found to be four days or earlier in relation to the expected AI.
This can be assessed to be up to 5.5 days before estimated ovulation
[14]. However, if the treatment was initiated one day later, the
response was variable with only 33e50% of the vixens responding
and therefore not becoming pregnant (Table 2). If the treatment
was initiated later than this, aromatase inhibition did not work and
the treated vixens became pregnant.
There were two probable reasons for the earlier than expected
onset of cyclicity for the experimental vixens that somewhat
complicated our experimental setting. Firstly, handling andmoving
vixens about within the farm, which was initiated already in
February, is known to hasten the onset of the breeding season [16].
Secondly, there are no efficient oestrus synchronization protocols
available for the fox. Therefore, due to this handling effect in the
females, the onset of natural heat occurred earlier than predicted
and we had more vixens than intended with initiation of treatment
in progressed pro-oestrus or even in oestrus. Moreover, it is also
possible that at initiation of treatment, in some vixens, ovulation
might have occurred and oocytes were under maturation and even
ready for fertilization. In this study, the interval from initiation of
treatment to first AI was on average between three to four days
which is clearly shorter than the average duration of pro-oestrus in
the vixens [14].
Regarding the VER values, characteristic profiles for blue fox
vixens were observed in this study. No statistically relevant dif-
ferences were established between the treatment groups. It is wellknown, that individual differences exist regarding the duration of
the period of high VER values (range one to three days [18]). Due to
this, as AIs were performed during the period of high VER, there
was a discrepancy in the number of AIs per vixen resulting in one or
two AIs in all except one vixen which had four AIs due to a two-
phase resistance curve. This routine AI protocol was accepted in
this study to provide all inseminated vixens an equal opportunity to
become pregnant. The vixens with two or more AIs were equally
distributed within each treatment group (3e5 per each) so their
effect is similar in all groups. In fox farming, VER values are the only
indicator used for prediction of ovulation in vixens. As described
previously by Møller et al. [18] and Farstad et al. [17], the VER
usually reaches maximum values around ovulation i.e., approxi-
mately two to three days after the oestradiol peak or half a day after
the LH peak [18]. A subsequent decrease of at least 50 U is
considered significant [14].
In the present study, no statistically significant differences were
observed in plasma oestradiol concentrations between placebo and
the treatment groups. Plasma levels of oestradiol-17-b are known
to increase from approximately one week prior to the LH peak.
Maximum oestradiol levels of 40e120 pg/mL (140e350 pmol/L) are
detected one day prior or on the day of the LH peak [17,18]. In this
study, increasing levels of oestradiol were measured starting
day 10 before the first AI, reaching peak values up to 400 pmol/L
in the placebo and BCD pregnant groups, five days prior to the first
AI. In the BCD not pregnant group, a lower peak of approximately
200 pmol/L was observed 4 days before first insemination. After
peak values, coindicing with the time of initiation of treatment,
oestradiol levels decreased to below 50 pmol/L approximately one
day before the first AI, maintaining low values during the luteal
phase. Oestradiol levels have been found to decrease rapidly
following the LH peak in vixens and remain low for several weeks
during the luteal phase [14]. Our results are similar and therefore, in
BCD pregnant vixens, the decrease in oestradiol concentration
during the period day 5 to the first AI may have occurred due to
the physiological decrease after the oestradiol and/or LH peak
Table 2
Pregnancy rates (%) in the individual treatment groups (A, B, C, D) and in the total of treated vixens (BCD) according to the number of days between initiation of treatment and
first AI.
Days between Pregnancy rate (n pregnant/n total inseminated) in group
initiation of treatment and first AI A n ¼ 19 B n ¼ 16 C N ¼ 18 D n ¼ 17 BCD n ¼ 51
0 100.0 (2/2) 100.0 (2/2)
1 100.0 (2/2) 100.0 (3/3) 100.0 (4/4) 100.0 (9/9)
2 100.0 (4/4) 100.0 (3/3) 100.0 (1/1) 100.0 (2/2) 100.0 (6/6)
3 100.0 (6/6) 85.7 (6/7) 66.7 (4/6) 50.0 (3/6) 68.4 (13/19)
4 100.0 (3/3) 50.0 (2/4) 0.0 (0/5) 0.0 (0/3) 16.7 (2/12)
5 100.0 (1/1) 0.0 (0/1) 0.0 (0/2) 0.0 (0/3)
6,7,9 60.0 (3/5)
Total 89.5 (17/19) 81.3 (13/16) 55.6 (10/18) 52.9 (9/17) 62.7 (32/51)
AI ¼ artificial insemination. Group A (placebo), group B (0.5 mg/kg), group C (3.5 mg/kg) and group D (24.5 mg/kg).
L. Lindh et al. / Theriogenology 152 (2020) 53e63 61rather than due to initiation of treatment with finrozole. Instead, in
the BCD not pregnant vixens, oestradiol concentration had not
reached a physiological peak at the initiation of treatment (in fact,
the values were still increasing as shown in Fig. 5) and therefore, in
this group, finrozole treatment may have influenced the oestradiol
profile and caused a decrease in oestradiol concentrations earlier
than it would physiologically have occurred.
Extraordinary high concentrations of oestradiol were found in
the 9th blood sample in two vixens of group C (667.2 and
644.9 pmol/L). On the other hand, three vixens (two in group C and
one in group D) had minor increases from 100 to 165 pmol/L in the
9th blood sample. In the latter group, one group C vixen had two
pups, the other group C vixen was negative in ultrasound and had
no pups and the group D vixen had two foetuses in ultrasound but
did not whelp. As the oestradiol increase was observed in both, not
pregnant and pregnant vixens, a causal connection with a recur-
rence of heat seems doubtful. This is supported by the fact, that in
all vixens the progesterone patterns indicated a normal and
continuous luteal phase.
In this study, no statistically significant differences were found in
peripheral progesterone values between treatment and placebo
groups. In each group, a rise in plasma progesterone values was
observed prior to first AI. The mean time period of treatment before
thefirstAIwas3.1±1.6days. In theplaceboandBCDpregnantgroups,
the first increase in progesterone concentration together with the
initial decreaseof theoestradiol concentrationwasobservedfivedays
before the first AI. This is in agreement with Farstad [14] who stated
that after a rapid decrease in oestradiol levels progesterone levels
increase rapidly from the first initial rise simultaneously with the LH
peak. The average progesterone values at the time of insemination
ranged between 100 and 230 nmol/L. According to Urlings et al. [28]
and Høier [29], progesterone values from 95 to 143 nmol/L indicate
that first AI should occur one day after blood sampling and values
above 143 nmol/L indicate that first AI should be performed on the
day of blood sampling. Based on this, the timing of AIs in this study
provided good prerequisites for fertilization.
In all groups, peak progesterone values ranging from 300 to
600 nmol/L were measured around 16e17 days after first AI.Table 3
Numbers of live pups (mean ± SD) counted at birth in the placebo and the individual tre
Number of live pups
Group /Inseminated vixe
A 7.9 ± 4.8, n ¼ 19
B 3.5 ± 4.5, n ¼ 16
C 2.9 ± 3.6, n ¼ 18
D 1.4 ± 2.4, n ¼ 17
Group A (placebo), group B (0.5 mg/kg), group C (3.5 mg/kg) and group D (24.5 mg/kg).Thereafter progesterone values began to decrease. In earlier studies
[30e32], the peak progesterone values were lower, reaching a
plateau five to 12 days after mating and remained high for
approximately two weeks. A clear plateau was not observed in the
present study. In addition, compared to the placebo group, a second
peak in progesterone concentrations seemed to occur in both
treatment groups approximately 28 days after the first AI. No such
peak was observed in the placebo group. A similar progesterone
pattern has been observed in unpublished studies on finrozole
treatment in female dogs. The second progesterone peak still needs
clarification.
From the results of the present study, it can be hypothetized that
prevention of oestradiol production by finrozole may have caused a
reorientation of steroid metabolism to other paths and therefore,
resulted in high progesterone values. In cattle, after treatment with
the non-steroidal aromatase inhibitor letrozole, higher than normal
progesterone values were detected [10e12]. In addition, adminis-
tration of aromatase inhibitors may alter the ovulatory process. In
rats, administration of letrozole resulted in polycystic ovaries and
caused incomplete luteinization and a decreased number of
corpora lutea [33]. In our study, the ovaries of the vixens were not
examined. However, as already mentioned above, in all vixens the
progesterone profiles appeared normal, indicating the presence of
either corpora lutea or luteinized follicles (reported earlier by Far-
stad et al. [17]).
Regarding the assessment of hormone patterns, an influence of
stress caused by handling of the vixens must be taken into
consideration. In a study on silver foxes that was started in animals
not used to handling, manipulations resulted in long-term stress,
high levels of fear-responses and enlarged adrenals [34]. Being
taken out of their cage with a neck-tongue should be regarded as a
stressor to vixens [35]. In our study, all vixens were primi- or
multiparous and therefore, experienced to handling prior to the
beginning of the study and familiar with the farm environment and
personnel.
The blood sampling was executed in anaesthetized vixens. In a
study in mice, the effects of both single and repeated anaesthesia
(six times at an interval of three to four days) were considered mildatment groups in relation to inseminated and whelping vixens.
n /Whelping vixen
9.4 ± 3.6, n ¼ 16
6.9 ± 4.1, n ¼ 8
5.8 ± 3.0, n ¼ 9
3.8 ± 2.8, n ¼ 6
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levels were assessed to be longer in mice that were repeatedly
anaesthetized. Short-term acute stressors often fail to affect
reproduction [37]. However, it seems possible that several times
repeated short-term handling stress during health inspections and
blood collections before and during pregnancy may have influ-
enced the reproductive outcome and increased perinatal pup loss
as was described for handling stress [38].
In the present study, 10 vixens diagnosed pregnant in ultra-
sound were not observed giving birth. During pregnancy, blue fox
vixens are known to experience both embryonic and foetal losses
[39]. They may also demolish born cubs, although infanticide is not
a common problem in blue foxes [27]. Naturally occurring post-
implantation pregnancy losses of 27.5% are reported for blue foxes
[39]. In our study, although the vixens were handled several times
during pregnancy, the proportion of lost pregnancies (20.4%) was
lower. The lost pregnancies were probably due to vixens experi-
encing resorption or giving birth to weak pups that died and were
eaten by their mothers. Abortions cannot be completely excluded.
However, abortion seems to occur seldom in blue fox vixens (0.5%
of barren vixens), thus indicating that resorption of embryos may
be a major factor affecting barrenness [40].
In the placebo group, the average number of live pups per
whelping vixen was 9.4. This is in agreement with other authors
reporting eight to ten live and dead pups per whelping vixen on the
first day postpartum [41e43]. In the treatment groups BCD, the
average number of live pups per whelping vixen varied from 3.8 to
6.9. The total number of live born pups in the three treatment
groups was 130 compared to 151 in the placebo group. Further-
more, in the treatment groups the litter size tended to be smaller
the longer the interval between initiation and first AI. If treatment
started less than 3 days before first AI, vixens had a maximum of
9e12 pups, if the interval between start of treatment and first AI
was 3 days or more, the maximum litter size was 2e6 pups.
Partial (n ¼ 19) or complete (n ¼ 2) losses of neonates occurred
in 53.8% of 39 litters within the first week of life. No deleterious
effects (for instance malformations) of finrozole on pups could be
verified. Interestingly, postnatal pup loss was more frequent in the
placebo group (23.8%) than in the treatment groups (5.5e11.5%).
The amount of losses was in accordance with the result of
Pyyk€onen et al. [44] who reported 32.7% and 16.7% of pup losses in
primiparous and multiparous vixens, respectively, from birth to
weaning.
In the present study, the efficacy of the treatment was signifi-
cantly affected by the stage of heat at the initiation of drug
administration (Fig. 6). Vixens that were inseminated three, four or
five days after the start of treatment with 3.5 mg/kg or 24.5 mg/kg
in an early stage of follicular development did not conceive. If
administration of finrozole was initiated close to AI (two to zero
days before first AI), none of the doses was successful for achieving
contraception as the stage of heat was too advanced.5. Conclusions
According to the results of this study, pregnancy in blue fox
vixens can be prevented by finrozole as long as treatment at doses
of 3.5 mg/kg or 24.5 mg/kg is initiated at least four days before the
first AI. Vixens that have not reached the oestradiol peak are sus-
ceptible to the treatment. Thus, careful detection of initial clinical
signs of heat will be required, which in bitches can usually be
achieved with little or no stress. Therefore, based on the results
shown in this study, the authors conclude that the use of aromatase
inhibitors could prove a promising tool for contraception in female
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